Product Code: TMRGL7718
The report provides revenue of the global antihypertensive drugs market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global antihypertensive drugs market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the antihypertensive drugs market.
The report delves into the competitive landscape of the global antihypertensive drugs market. Key players operating in the global antihypertensive drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global antihypertensive drugs market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Antihypertensive Drugs Market
4. Market Overview
- 4.1. Introduction
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Antihypertensive Drugs Market Analysis and Forecast, 2017-2031
- 4.4.1. Market Revenue Projections (US$ Bn)
5. Market Outlook
- 5.1. Key Industry Developments
- 5.2. Impact scenario
- 5.3. New product developments
6. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Therapy Type
- 6.1. Introduction & Definition
- 6.2. Global Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
- 6.2.1. Diuretics
- 6.2.1.1. Thiazide diuretics
- 6.2.1.2. Loop diuretics
- 6.2.1.3. Potassium-sparing diuretics
- 6.2.2. Angiotensin Converting Enzyme Inhibitors
- 6.2.3. Angiotensin Receptor Blockers
- 6.2.4. Beta-blockers
- 6.2.4.1. Beta-1 Selective
- 6.2.4.2. Intrinsic Sympathomimetic
- 6.2.5. Vasodilators
- 6.2.6. Calcium Channel Blockers
- 6.2.7. Renin Inhibitors
- 6.2.8. Alpha-blockers
- 6.2.9. Others
- 6.3. Global Antihypertensive Drugs Market Attractiveness, by Therapy Type
7. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Type
- 7.1. Introduction & Definition
- 7.2. Global Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
- 7.2.1. Primary Hypertension
- 7.2.2. Secondary Hypertension
- 7.3. Global Antihypertensive Drugs Market Attractiveness, by Type
8. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Medication Type
- 8.1. Introduction
- 8.2. Global Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
- 8.2.1. Monotherapy
- 8.2.2. Combination Therapy
- 8.2.3. Fixed Dose Combinations
- 8.3. Global Antihypertensive Drugs Market Attractiveness, by Medication Type
9. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Distribution Channel
- 9.1. Introduction
- 9.2. Global Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
- 9.2.1. Retail Pharmacies
- 9.2.2. Hospital Pharmacies
- 9.2.3. Online Pharmacies
- 9.2.4. Others
- 9.3. Global Antihypertensive Drugs Market Attractiveness, by Distribution Channel
10. Global Antihypertensive Drugs Market Value (US$ Bn) Forecast, by Region
- 10.1. Introduction
- 10.2. Antihypertensive Drugs Market Value Forecast, by Region, 2017-2031
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
- 10.3. Global Antihypertensive Drugs Market Attractiveness, by Region
11. North America Antihypertensive Drugs Market Analysis and Forecast
- 11.1. Introduction
- 11.2. North America Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
- 11.2.1. Diuretics
- 11.2.1.1. Thiazide diuretics
- 11.2.1.2. Loop diuretics
- 11.2.1.3. Potassium-sparing diuretics
- 11.2.2. Angiotensin Converting Enzyme Inhibitors
- 11.2.3. Angiotensin Receptor Blockers
- 11.2.4. Beta-blockers
- 11.2.4.1. Beta-1 Selective
- 11.2.4.2. Intrinsic Sympathomimetic
- 11.2.5. Vasodilators
- 11.2.6. Calcium Channel Blockers
- 11.2.7. Renin Inhibitors
- 11.2.8. Alpha-blockers
- 11.2.9. Others
- 11.3. North America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
- 11.3.1. Primary Hypertension
- 11.3.2. Secondary Hypertension
- 11.4. North America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
- 11.4.1. Monotherapy
- 11.4.2. Combination Therapy
- 11.4.3. Fixed Dose Combinations
- 11.4.4. Others
- 11.5. North America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
- 11.5.1. Retail Pharmacies
- 11.5.2. Hospital Pharmacies
- 11.5.3. Online Pharmacies
- 11.5.4. Others
- 11.6. North America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.6.1. U.S.
- 11.6.2. Canada
- 11.7. North America Antihypertensive Drugs Market Attractiveness Analysis
- 11.7.1. By Therapy Type
- 11.7.2. By Type
- 11.7.3. By Medication Type
- 11.7.4. By Distribution Channel
- 11.7.5. By Country/Sub-region
12. Europe Antihypertensive Drugs Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Europe Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
- 12.2.1. Diuretics
- 12.2.1.1. Thiazide diuretics
- 12.2.1.2. Loop diuretics
- 12.2.1.3. Potassium-sparing diuretics
- 12.2.2. Angiotensin Converting Enzyme Inhibitors
- 12.2.3. Angiotensin Receptor Blockers
- 12.2.4. Beta-blockers
- 12.2.4.1. Beta-1 Selective
- 12.2.4.2. Intrinsic Sympathomimetic
- 12.2.5. Vasodilators
- 12.2.6. Calcium Channel Blockers
- 12.2.7. Renin Inhibitors
- 12.2.8. Alpha-blockers
- 12.2.9. Others
- 12.3. Europe Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
- 12.3.1. Primary Hypertension
- 12.3.2. Secondary Hypertension
- 12.4. Europe Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
- 12.4.1. Monotherapy
- 12.4.2. Combination Therapy
- 12.4.3. Fixed Dose Combinations
- 12.4.4. Others
- 12.5. Europe Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
- 12.5.1. Retail Pharmacies
- 12.5.2. Hospital Pharmacies
- 12.5.3. Online Pharmacies
- 12.5.4. Others
- 12.6. Europe Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.6.4. Spain
- 12.6.5. Italy
- 12.6.6. Rest of Europe
- 12.7. Europe Antihypertensive Drugs Market Attractiveness Analysis
- 12.7.1. By Therapy Type
- 12.7.2. By Type
- 12.7.3. By Medication Type
- 12.7.4. By Distribution Channel
- 12.7.5. By Country/Sub-region
13. Asia Pacific Antihypertensive Drugs Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
- 13.2.1. Diuretics
- 13.2.1.1. Thiazide diuretics
- 13.2.1.2. Loop diuretics
- 13.2.1.3. Potassium-sparing diuretics
- 13.2.2. Angiotensin Converting Enzyme Inhibitors
- 13.2.3. Angiotensin Receptor Blockers
- 13.2.4. Beta-blockers
- 13.2.4.1. Beta-1 Selective
- 13.2.4.2. Intrinsic Sympathomimetic
- 13.2.5. Vasodilators
- 13.2.6. Calcium Channel Blockers
- 13.2.7. Renin Inhibitors
- 13.2.8. Alpha-blockers
- 13.2.9. Others
- 13.3. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
- 13.3.1. Primary Hypertension
- 13.3.2. Secondary Hypertension
- 13.4. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
- 13.4.1. Monotherapy
- 13.4.2. Combination Therapy
- 13.4.3. Fixed Dose Combinations
- 13.4.4. Others
- 13.5. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
- 13.5.1. Retail Pharmacies
- 13.5.2. Hospital Pharmacies
- 13.5.3. Online Pharmacies
- 13.5.4. Others
- 13.6. Asia Pacific Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. Japan
- 13.6.2. China
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
- 13.7. Asia Pacific Antihypertensive Drugs Market Attractiveness Analysis
- 13.7.1. By Therapy Type
- 13.7.2. By Type
- 13.7.3. By Medication Type
- 13.7.4. By Distribution Channel
- 13.7.5. By Country/Sub-region
14. Latin America Antihypertensive Drugs Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Latin America Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
- 14.2.1. Diuretics
- 14.2.1.1. Thiazide diuretics
- 14.2.1.2. Loop diuretics
- 14.2.1.3. Potassium-sparing diuretics
- 14.2.2. Angiotensin Converting Enzyme Inhibitors
- 14.2.3. Angiotensin Receptor Blockers
- 14.2.4. Beta-blockers
- 14.2.4.1. Beta-1 Selective
- 14.2.4.2. Intrinsic Sympathomimetic
- 14.2.5. Vasodilators
- 14.2.6. Calcium Channel Blockers
- 14.2.7. Renin Inhibitors
- 14.2.8. Alpha-blockers
- 14.2.9. Others
- 14.3. Latin America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
- 14.3.1. Primary Hypertension
- 14.3.2. Secondary Hypertension
- 14.4. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
- 14.4.1. Monotherapy
- 14.4.2. Combination Therapy
- 14.4.2.1. Thiazide diuretics
- 14.4.2.2. Loop diuretics
- 14.4.2.3. Potassium-sparing diuretics
- 14.4.3. Angiotensin Converting Enzyme Inhibitors
- 14.4.4. Angiotensin Receptor Blockers
- 14.4.5. Beta-blockers
- 14.4.5.1. Beta-1 Selective
- 14.4.5.2. Intrinsic Sympathomimetic
- 14.4.6. Vasodilators
- 14.4.7. Calcium Channel Blockers
- 14.4.8. Renin Inhibitors
- 14.4.9. Alpha-blockers
- 14.4.10. Others
- 14.5. Latin America Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
- 14.5.1. Primary Hypertension
- 14.5.2. Secondary Hypertension
- 14.6. Latin America Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
- 14.6.1. Monotherapy
- 14.6.2. Combination Therapy
- 14.6.3. Fixed Dose Combinations
- 14.6.4. Others
- 14.7. Latin America Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
- 14.7.1. Retail Pharmacies
- 14.7.2. Hospital Pharmacies
- 14.7.3. Online Pharmacies
- 14.7.4. Others
- 14.8. Latin America Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.8.1. Brazil
- 14.8.2. Mexico
- 14.8.3. Rest of Latin America
- 14.9. Latin America Antihypertensive Drugs Market Attractiveness Analysis
- 14.9.1. By Therapy Type
- 14.9.2. By Type
- 14.9.3. By Medication Type
- 14.9.4. By Distribution Channel
- 14.9.5. By Country/Sub-region
15. Middle East & Africa Antihypertensive Drugs Market Analysis and Forecast
- 15.1. Introduction
- 15.2. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Therapy Type, 2017-2031
- 15.2.1. Diuretics
- 15.2.1.1. Thiazide diuretics
- 15.2.1.2. Loop diuretics
- 15.2.1.3. Potassium-sparing diuretics
- 15.2.2. Angiotensin Converting Enzyme Inhibitors
- 15.2.3. Angiotensin Receptor Blockers
- 15.2.4. Beta-blockers
- 15.2.4.1. Beta-1 Selective
- 15.2.4.2. Intrinsic Sympathomimetic
- 15.2.5. Vasodilators
- 15.2.6. Calcium Channel Blockers
- 15.2.7. Renin Inhibitors
- 15.2.8. Alpha-blockers
- 15.2.9. Others
- 15.3. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Type, 2017-2031
- 15.3.1. Primary Hypertension
- 15.3.2. Secondary Hypertension
- 15.4. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Medication Type, 2017-2031
- 15.4.1. Monotherapy
- 15.4.2. Combination Therapy
- 15.4.3. Fixed Dose Combinations
- 15.4.4. Others
- 15.5. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Distribution Channel, 2017-2031
- 15.5.1. Retail Pharmacies
- 15.5.2. Hospital Pharmacies
- 15.5.3. Online Pharmacies
- 15.5.4. Others
- 15.6. Middle East & Africa Antihypertensive Drugs Market Value Forecast, by Country/Sub-region, 2017-2031
- 15.6.1. GCC Countries
- 15.6.2. South Africa
- 15.6.3. Israel
- 15.6.4. Rest of Middle East & Africa
- 15.7. Middle East & Africa Antihypertensive Drugs Market Attractiveness Analysis
- 15.7.1. By Therapy Type
- 15.7.2. By Type
- 15.7.3. By Medication Type
- 15.7.4. By Distribution Channel
- 15.7.5. By Country/Sub-region
16. Competition Landscape
- 16.1. Market Player - Competition Matrix (by tier and size of companies)
- 16.2. Company Profiles
- 16.2.1. Pfizer, Inc.
- 16.2.1.1. Company Description
- 16.2.1.2. Business Overview
- 16.2.1.3. Financial Overview
- 16.2.1.4. Strategic Overview
- 16.2.1.5. SWOT Analysis
- 16.2.2. Sanofi S.A
- 16.2.2.1. Company Description
- 16.2.2.2. Business Overview
- 16.2.2.3. Financial Overview
- 16.2.2.4. Strategic Overview
- 16.2.2.5. SWOT Analysis
- 16.2.3. Novartis AG
- 16.2.3.1. Company Description
- 16.2.3.2. Business Overview
- 16.2.3.3. Financial Overview
- 16.2.3.4. Strategic Overview
- 16.2.3.5. SWOT Analysis
- 16.2.4. Boehringer Ingelheim GmbH
- 16.2.4.1. Company Description
- 16.2.4.2. Business Overview
- 16.2.4.3. Financial Overview
- 16.2.4.4. Strategic Overview
- 16.2.4.5. SWOT Analysis
- 16.2.5. Actelion Ltd. (Johnson & Johnson Services, Inc.)
- 16.2.5.1. Company Description
- 16.2.5.2. Business Overview
- 16.2.5.3. Financial Overview
- 16.2.5.4. Strategic Overview
- 16.2.5.5. SWOT Analysis
- 16.2.6. F. Hoffmann-La Roche Ltd.
- 16.2.6.1. Company Description
- 16.2.6.2. Business Overview
- 16.2.6.3. Financial Overview
- 16.2.6.4. Strategic Overview
- 16.2.6.5. SWOT Analysis
- 16.2.7. Bayer AG
- 16.2.7.1. Company Description
- 16.2.7.2. Business Overview
- 16.2.7.3. Financial Overview
- 16.2.7.4. Strategic Overview
- 16.2.7.5. SWOT Analysis
- 16.2.8. Daiichi Sankyo Company, Limited
- 16.2.8.1. Company Description
- 16.2.8.2. Business Overview
- 16.2.8.3. Financial Overview
- 16.2.8.4. Strategic Overview
- 16.2.8.5. SWOT Analysis
- 16.2.9. Takeda Pharmaceutical Company Limited
- 16.2.9.1. Company Description
- 16.2.9.2. Business Overview
- 16.2.9.3. Financial Overview
- 16.2.9.4. Strategic Overview
- 16.2.9.5. SWOT Analysis